Search results for "Guide"

showing 10 items of 1478 documents

The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update

2014

This guideline is the result of a systematic literature review using the 'Grading of Recommendations Assessment, Development and Evaluation' (GRADE) methodology and a structured consensus conference held on 28 and 29 November 2012, in Berlin. It is a joint initiative of the Dermatology Section of the European Academy of Allergy and Clinical Immunology (EAACI), the EU-funded network of excellence, the Global Allergy and Asthma European Network (GA(2)LEN), the European Dermatology Forum (EDF), and the World Allergy Organization (WAO) with the participation of delegates of 21 national and international societies. Urticaria is a frequent, mast cell-driven disease, presenting with wheals, angioe…

Allergymedicine.medical_specialtyhivesImmunologylcsh:Medicine610 Medicine & healthDermatologyDiseaseurticariaimmune system diseaseslcsh:DermatologyHumansImmunology and AllergyMedicinemedia_common.cataloged_instanceEuropean unionskin and connective tissue diseaseswhealAsthmamedia_common2403 ImmunologyAcute urticariaAngioedemabusiness.industryangioedemalcsh:RConsensus conferenceangioedema; consensus; hives; urticaria; wheal; Humans; Urticaria10177 Dermatology ClinicGuidelinelcsh:RL1-803angioedema consensus hives urticaria wheal CHRONIC IDIOPATHIC URTICARIA QUALITY-OF-LIFE SERUM SKIN-TEST DELAYED PRESSURE URTICARIA DOSE INTRAVENOUS IMMUNOGLOBULIN ANTIIMMUNOGLOBULIN-E THERAPY RESISTANT CHRONIC URTICARIA RANDOMIZED CONTROLLED-TRIAL ULTRAVIOLET-B PHOTOTHERAPY WORLD-HEALTH-ORGANIZATIONmedicine.diseaseDermatologySystematic reviewconsensusFamily medicine2723 Immunology and Allergymedicine.symptombusinessAllergy
researchProduct

Mechanisms of Spontaneous and Amplified Spontaneous Emission in CH3NH3PbI3 Perovskite Thin Films Integrated in an Optical Waveguide

2020

In this paper, the physical mechanisms responsible for optical gain in ${\mathrm{CH}}_{3}{\mathrm{NH}}_{3}{\mathrm{Pb}\mathrm{I}}_{3}$ (MAPI) polycrystalline thin films are investigated experimentally and theoretically. Waveguide structures composed by a MAPI film embedded in between PMMA and silica layers are used as an efficient geometry to confine emitted light in MAPI films and minimize the energy threshold for amplified spontaneous emission (ASE). We show that photogenerated exciton density at the ASE threshold is as low as $(2.4\ensuremath{-}12)\ifmmode\times\else\texttimes\fi{}{10}^{16}\phantom{\rule{0.1em}{0ex}}{\mathrm{cm}}^{\ensuremath{-}3}$, which is below the Mott transition den…

Amplified spontaneous emissionMaterials scienceExcitonPhysics::OpticsGeneral Physics and Astronomy02 engineering and technology021001 nanoscience & nanotechnology01 natural sciencesMolecular physicsWaveguide (optics)Mott transitionCondensed Matter::Materials Science0103 physical sciencesSpontaneous emissionThin film010306 general physics0210 nano-technologyEnergy (signal processing)Perovskite (structure)Physical Review Applied
researchProduct

Optical gain, spontaneous and stimulated emission of surface plasmon polaritons in confined plasmonic waveguide

2010

International audience; We develop a theoretical model to compute the local density of states in a confined plasmonic waveguide. Based on this model, we derive a simple formula with a clear physical interpretation for the lifetime modification of emitters embedded in the waveguide. The gain distribution within the active medium is then computed following the formalism developed in a recent work [Phys. Rev. B 78, 161401 (2008)], by taking rigorously into account the pump irradiance and emitters lifetime modifications in the system. We finally apply this formalism to describe gain–assisted propagation in a dielectric–loaded surface plasmon polariton waveguide.

Amplified spontaneous emissionWaveguide (electromagnetism)Optical amplifiersLightPhysics::Optics02 engineering and technologySurface plasmons01 natural sciences010309 opticsOptics0103 physical sciencesScattering RadiationComputer SimulationSpontaneous emissionStimulated emission[SPI.NANO]Engineering Sciences [physics]/Micro and nanotechnologies/MicroelectronicsOptical amplifierPhysicsQuantum electrodynamicsbusiness.industrySurface plasmonOptical DevicesEquipment DesignModels TheoreticalSurface Plasmon ResonanceWeights and Measures021001 nanoscience & nanotechnologySurface plasmon polaritonAtomic and Molecular Physics and OpticsComputer-Aided DesignOptoelectronics[ SPI.NANO ] Engineering Sciences [physics]/Micro and nanotechnologies/MicroelectronicsQuantum electrodynamics.0210 nano-technologybusiness(240.6680) Surface plasmons; (230.4480) Optical amplifiers; (020.5580) Quantum electrodynamics.Localized surface plasmon
researchProduct

PHARMACOLOGICAL MANAGEMENT OF THE POLYTRAUMA PATIENT. ON ANALGESIC THERAPY GUIDELINES

2022

In consideration of the constant, if not increasing number of polytrauma patients arriving in emergency rooms, the pharmacological treatment of pain is a topic that is always under observation and innovation. Even more important is the global management of pain in the polytrauma patient, i.e. its treatment in the phases even after hospitalisation. The existence of pharmacotherapeutic protocols is today an aid for the physician in order to act in the most appropriate way in the shortest possible time. This brief commentary is intended to be a practical guide to the analgesic treatment of the polytrauma patient, in the light of the most recent scientific evidence.

Analgesic Guidelines Polytrauma Management Pharmacology Surveillance.
researchProduct

Sympathetic blocks for visceral cancer pain management: A systematic review and EAPC recommendations.

2015

The neurolytic blocks of sympathetic pathways, including celiac plexus block (CPB) and superior hypogastric plexus block (SHPB) , have been used for years. The aim of this review was to assess the evidence to support the performance of sympathetic blocks in cancer patients with abdominal visceral pain. Only comparison studies were included. All data from the eligible trials were analyzed using the GRADE system. Twenty-seven controlled studies were considered. CPB, regardless of the technique used, improved analgesia and/or decrease opioid consumption, and decreased opioid-induced adverse effects in comparison with a conventional analgesic treatment. In one study patients treated with superi…

AnalgesicPainOpioidmedicine.nerveSympathetic blockSuperior hypogastric plexusMedicineHumansPain ManagementCancer painAdverse effectAutonomic Nerve BlockIntention-to-treat analysisbusiness.industryCeliac plexus blockVisceral painHematologyAnalgesics OpioidEuropeOncologySample size determinationAnesthesiaAbdominal NeoplasmsPractice Guidelines as Topicmedicine.symptomGeriatrics and GerontologybusinessCancer painSuperior hypogastric plexus blockAutonomic Nerve BlockCritical reviews in oncology/hematology
researchProduct

A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working grou…

2016

The US National Cancer Institute estimates that cardiotoxicity (CTX) from target therapy refers mostly to four groups of drugs: epidermal growth factor receptor 2 inhibitors, angiogenic inhibitors, directed Abelson murine leukemia viral oncogene homolog inhibitors, and proteasome inhibitors. The main cardiotoxic side-effects related to antiepidermal growth factor receptor 2 therapy are left ventricular systolic dysfunction and heart failure. Angiogenesis inhibitors are associated with hypertension, left ventricular dysfunction/heart failure, myocardial ischemia, QT prolongation, and thrombosis. Moreover, other agents may be related to CTX induced by treatment. In this study, we review the g…

AngiogenesisLeftAngiogenesis Inhibitors030204 cardiovascular system & hematologyVentricular Dysfunction Left0302 clinical medicinetyrosine kinase inhibitorNeoplasmstyrosine kinase inhibitorsVentricular DysfunctionMolecular Targeted TherapyEpidermal growth factor receptorSocieties Medicalangiogenesis inhibitors; HER2/epidermal growth factor receptor 2; tyrosine kinase inhibitorABLbiologyDisease ManagementGeneral MedicineItalyCardiovascular DiseasesSupplement Submission030220 oncology & carcinogenesisangiogenesis inhibitors; HER2/epidermal growth factor receptor 2; tyrosine kinase inhibitors; Angiogenesis Inhibitors; Antineoplastic Agents; Cardiology; Cardiomyopathies; Cardiotoxicity; Heart Failure; Humans; Italy; Neoplasms; Practice Guidelines as Topic; Societies Medical; Ventricular Dysfunction Left; Disease ManagementPractice Guidelines as TopicCardiologyCardiology and Cardiovascular MedicineCardiomyopathiesmedicine.medical_specialtyCardiologyAntineoplastic AgentsRisk AssessmentQT interval03 medical and health sciencesGrowth factor receptorInternal medicineMedicalmedicineHumansMonitoring PhysiologicHeart FailureCardiotoxicitybusiness.industryCancerHER2/epidermal growth factor receptor 2medicine.diseaseangiogenesis inhibitors; HER2/epidermal growth factor receptor 2; tyrosine kinase inhibitors; Cardiology and Cardiovascular MedicineCardiotoxicityangiogenesis inhibitorHeart failurebiology.proteinbusinessSocietiesJournal of cardiovascular medicine (Hagerstown, Md.)
researchProduct

Changes in Body Composition in Anorexia Nervosa : Predictors of Recovery and Treatment Outcome

2015

The restoration of body composition (BC) parameters is considered to be one of the most important goals in the treatment of patients with anorexia nervosa (AN). However, little is known about differences between AN diagnostic subtypes [restricting (AN-R) and binge/purging (AN-BP)] and weekly changes in BC during refeeding treatment. Therefore, the main objectives of our study were twofold: 1) to assess the changes in BC throughout nutritional treatment in an AN sample and 2) to analyze predictors of BC changes during treatment, as well as predictors of treatment outcome. The whole sample comprised 261 participants [118 adult females with AN (70 AN-R vs. 48 AN-BP), and 143 healthy controls].…

Anorexia Nervosa:Psychiatry and Psychology::Mental Disorders::Eating Disorders::Binge-Eating Disorder [Medical Subject Headings]Body water:Phenomena and Processes::Physiological Phenomena::Body Constitution::Body Weights and Measures::Body Mass Index [Medical Subject Headings]lcsh:MedicineÍndice de masa corporalAnorexia nervosaMetabolismo basal:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]FatsImpedancia eléctricaadolescentslcsh:Science:Psychiatry and Psychology::Mental Disorders::Eating Disorders::Anorexia Nervosa [Medical Subject Headings]eating-disordersBody mass indexMetasMultidisciplinaryBulimia nervosaFemeninoAnorèxia nerviosaTrastorno por atracónModelos logísticos:Anatomy::Tissues::Connective Tissue::Adipose Tissue [Medical Subject Headings]HumanosTreatment OutcomeBasal metabolic rate measurementfat distributionbioelectrical-impedanceBody CompositionEating disordersObesitatFemalewomenmedicine.symptomBioelectrical impedance analysisResearch ArticleAdultTejido adiposomedicine.medical_specialtyPatient Dropoutsweight-gainwaterPes corporal:Anatomy::Fluids and Secretions::Body Fluids::Body Water [Medical Subject Headings]Anorexia nerviosa:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Motivation::Goals [Medical Subject Headings]Internal medicine:Health Care::Health Care Quality Access and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Outcome and Process Assessment (Health Care)::Outcome Assessment (Health Care)::Treatment Outcome [Medical Subject Headings]medicineTreatment guidelinesHumansObesityComposición corporal:Health Care::Health Care Quality Access and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Statistics as Topic::Models Statistical::Logistic Models [Medical Subject Headings]Trastorns de la conducta alimentàriabusiness.industrylcsh:Renergy-expenditureduration:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Techniques Endocrine::Thyroid Function Tests::Basal Metabolism [Medical Subject Headings]:Phenomena and Processes::Chemical Phenomena::Biochemical Phenomena::Body Composition [Medical Subject Headings]Anorexia nervosaBody weightmedicine.diseaseObesityAgua corporalEndocrinology:Check Tags::Female [Medical Subject Headings]Bulimia nervosaCase-Control StudiesBasal metabolic ratelcsh:QResultado del tratamiento:Phenomena and Processes::Physical Phenomena::Magnetic Phenomena::Electromagnetic Phenomena::Electricity::Electric Conductivity::Electric Impedance [Medical Subject Headings]businessBody mass indexWeight gain
researchProduct

Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study

2016

Background: Atrial fibrillation (AF) is associated with a substantial risk of thromboembolism and mortality, significantly reduced by oral anticoagulation. Adherence to guidelines may lower the risks for both all cause and cardiovascular (CV) deaths. Methods: Our objective was to evaluate if antithrombotic prophylaxis according to the 2012 European Society of Cardiology (ESC) guidelines is associated to a lower rate of adverse outcomes. Data were obtained from REPOSI; a prospective observational study enrolling inpatients aged ≥65 years. Patients enrolled in 2012 and 2014 discharged with an AF diagnosis were analysed. Results: Among 2535 patients, 558 (22.0 %) were discharged with a diagnos…

Antithrombotic therapy; Atrial fibrillation; Elderly; Guidelines; Outcomes; Cardiology and Cardiovascular MedicineMaleRegistrieTime Factorsantithrombotic therapy; atrial fibrillation; elderly; guidelines; outcomesAtrial fibrillation (AF)Practice PatternsKaplan-Meier Estimate030204 cardiovascular system & hematologyGuidelineoutcomesCoronary artery disease0302 clinical medicineElderlyRisk FactorsAtrial FibrillationAntithrombotic80 and overAge Factor030212 general & internal medicineRegistriesguidelinesAntithrombotic therapy Atrial fibrillation Elderly Guidelines OutcomesPractice Patterns Physicians'OutcomeAged 80 and overFibrinolytic AgentAge FactorsAtrial fibrillationGeneral MedicineTreatment OutcomeItalyAtrial fibrillation (AF) thromboembolism antithrombotic prophylaxisPractice Guidelines as TopicCardiologyFemaleGuideline AdherenceCardiology and Cardiovascular MedicineHumanAntithrombotic therapy; Atrial fibrillation; Elderly; Guidelines; Outcomes; Age Factors; Aged; Aged 80 and over; Atrial Fibrillation; Chi-Square Distribution; Female; Fibrinolytic Agents; Guideline Adherence; Humans; Italy; Kaplan-Meier Estimate; Logistic Models; Male; Practice Patterns Physicians'; Proportional Hazards Models; Registries; Risk Assessment; Risk Factors; Thromboembolism; Time Factors; Treatment Outcome; Practice Guidelines as Topic; Cardiology and Cardiovascular Medicinemedicine.medical_specialtyLogistic ModelTime FactorSocio-culturaleLower riskRisk Assessment03 medical and health sciencesFibrinolytic AgentsInternal medicineThromboembolismmedicineHumansProportional Hazards ModelsAgedAntithrombotic therapyPhysicians'Chi-Square Distributionbusiness.industryProportional hazards modelRisk FactorSettore MED/09 - MEDICINA INTERNAGuidelinethromboembolismmedicine.diseaseAtrial fibrillationLogistic ModelsProportional Hazards Modelantithrombotic prophylaxisbusinessChi-squared distributionFibrinolytic agent
researchProduct

2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism.

2018

Graves' disease (GD) is a systemic autoimmune disorder characterized by the infiltration of thyroid antigen-specific T cells into thyroid-stimulating hormone receptor (TSH-R)-expressing tissues. Stimulatory autoantibodies (Ab) in GD activate the TSH-R leading to thyroid hyperplasia and unregulated thyroid hormone production and secretion. Diagnosis of GD is straightforward in a patient with biochemically confirmed thyrotoxicosis, positive TSH-R-Ab, a hypervascular and hypoechoic thyroid gland (ultrasound), and associated orbitopathy. In GD, measurement of TSH-R-Ab is recommended for an accurate diagnosis/differential diagnosis, prior to stopping antithyroid drug (ATD) treatment and during p…

Antithyroid drugs; Graves' hyperthyroidism; Graves' orbitopathy; Management; Radioiodine therapy; Thyroidectomy;medicine.medical_specialtyendocrine systemendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolismGuidelinesGastroenterologyGraves' orbitopathy03 medical and health sciences0302 clinical medicineRadioiodine therapyInternal medicinemedicinePregnancyGraves' hyperthyroidismAntithyroid drugsbusiness.industryThyroidThyroidectomyAutoantibodymedicine.diseaseManagementmedicine.anatomical_structureHormone receptor030220 oncology & carcinogenesisThyroidectomyPropylthiouracilDifferential diagnosisbusinessHormonemedicine.drugEuropean thyroid journal
researchProduct

European society of hypertension position paper on ambulatory blood pressure monitoring

2013

Ambulatory blood pressure monitoring (ABPM) is being used increasingly in both clinical practice and hypertension research. Although there are many guidelines that emphasize the indications for ABPM, there is no comprehensive guideline dealing with all aspects of the technique. It was agreed at a consensus meeting on ABPM in Milan in 2011 that the 34 attendees should prepare a comprehensive position paper on the scientific evidence for ABPM.This position paper considers the historical background, the advantages and limitations of ABPM, the threshold levels for practice, and the cost-effectiveness of the technique. It examines the need for selecting an appropriate device, the accuracy of dev…

Arterial hypertensionmedicine.medical_specialtyAmbulatory blood pressurePhysiologyMEDLINEWhite coat hypertension030204 cardiovascular system & hematologylaw.invention03 medical and health sciencesresearch application0302 clinical medicineRandomized controlled triallawInternal Medicinemedicine030212 general & internal medicineguidelinesIntensive care medicineambulatory blood pressure monitoring clinic blood pressure measurement clinical indications guidelines home blood pressure measurement recommendations research applicationReimbursementbusiness.industryGuidelinemedicine.diseasehome blood pressure measurement3. Good healthMasked Hypertensionambulatory blood pressure monitoringrecommendationsPosition paperclinic blood pressure measurementCardiology and Cardiovascular Medicinebusinessclinical indications
researchProduct